Dimensional Fund Advisors LP grew its holdings in Stryker Co. (NYSE:SYK) by 0.2% in the 4th quarter, HoldingsChannel reports. The firm owned 696,849 shares of the medical technology company’s stock after buying an additional 1,642 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Stryker were worth $109,226,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Northwest Wealth Management LLC raised its stake in shares of Stryker by 103.6% during the 4th quarter. Northwest Wealth Management LLC now owns 169 shares of the medical technology company’s stock worth $26,000 after acquiring an additional 86 shares in the last quarter. Horan Securities Inc. bought a new position in shares of Stryker during the 4th quarter worth approximately $30,000. Truehand Inc bought a new position in shares of Stryker during the 4th quarter worth approximately $30,000. WESPAC Advisors SoCal LLC bought a new position in shares of Stryker during the 4th quarter worth approximately $34,000. Finally, Westside Investment Management Inc. raised its stake in shares of Stryker by 38.7% during the 4th quarter. Westside Investment Management Inc. now owns 233 shares of the medical technology company’s stock worth $37,000 after acquiring an additional 65 shares in the last quarter. Institutional investors and hedge funds own 74.71% of the company’s stock.
In other news, Chairman Kevin Lobo sold 41,750 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $194.11, for a total value of $8,104,092.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Timothy J. Scannell sold 4,666 shares of the company’s stock in a transaction on Tuesday, February 19th. The shares were sold at an average price of $186.25, for a total transaction of $869,042.50. The disclosure for this sale can be found here. Insiders sold a total of 111,550 shares of company stock worth $21,374,171 over the last ninety days. Insiders own 7.20% of the company’s stock.
Several research analysts recently commented on SYK shares. BTIG Research boosted their price objective on shares of Stryker to $211.00 and gave the stock a “buy” rating in a research note on Monday, March 18th. Piper Jaffray Companies reissued an “overweight” rating and set a $205.00 target price on shares of Stryker in a research report on Friday, March 1st. Barclays boosted their target price on shares of Stryker from $203.00 to $211.00 and gave the stock an “overweight” rating in a research report on Monday, April 15th. SunTrust Banks boosted their target price on shares of Stryker to $205.00 and gave the stock a “positive” rating in a research report on Monday, February 4th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Stryker from $200.00 to $215.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 19th. Seven investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $196.89.
SYK stock opened at $185.67 on Thursday. The firm has a market capitalization of $68.73 billion, a PE ratio of 25.40, a price-to-earnings-growth ratio of 2.24 and a beta of 0.84. The company has a current ratio of 2.12, a quick ratio of 1.30 and a debt-to-equity ratio of 0.68. Stryker Co. has a 12 month low of $144.75 and a 12 month high of $199.85.
Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, April 23rd. The medical technology company reported $1.88 EPS for the quarter, beating the consensus estimate of $1.84 by $0.04. The business had revenue of $3.52 billion for the quarter, compared to the consensus estimate of $3.51 billion. Stryker had a net margin of 25.38% and a return on equity of 26.72%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the prior year, the firm earned $1.68 EPS. On average, research analysts expect that Stryker Co. will post 8.15 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th will be issued a $0.52 dividend. This represents a $2.08 annualized dividend and a dividend yield of 1.12%. The ex-dividend date is Thursday, June 27th. Stryker’s dividend payout ratio (DPR) is currently 28.45%.
TRADEMARK VIOLATION WARNING: This piece was first posted by Transcript Daily and is the property of of Transcript Daily. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://transcriptdaily.com/2019/05/16/dimensional-fund-advisors-lp-acquires-1642-shares-of-stryker-co-syk.html.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.